

Global Chemotherapy Drugs for Neuroblastoma Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G53CDFC7CEDBEN.html>

Date: July 2023

Pages: 103

Price: US\$ 3,480.00 (Single User License)

ID: G53CDFC7CEDBEN

Abstracts

According to our (Global Info Research) latest study, the global Chemotherapy Drugs for Neuroblastoma market size was valued at USD 126.6 million in 2022 and is forecast to a readjusted size of USD 171.1 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

This report is a detailed and comprehensive analysis for global Chemotherapy Drugs for Neuroblastoma market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Chemotherapy Drugs for Neuroblastoma market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices

(US\$/Unit), 2018-2029

Global Chemotherapy Drugs for Neuroblastoma market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Chemotherapy Drugs for Neuroblastoma market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Chemotherapy Drugs for Neuroblastoma market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Chemotherapy Drugs for Neuroblastoma

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Chemotherapy Drugs for Neuroblastoma market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals and Qilu Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Chemotherapy Drugs for Neuroblastoma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and

value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Cyclophosphamide

Cisplatin or Carboplatin

Vincristine

Doxorubicin (Adriamycin)

Etoposide

Other

Market segment by Application

Hospital

Clinic

Other

Major players covered

Baxter Healthcare

Ingenus Pharmaceuticals

ANI Pharmaceuticals

Teva Pharmaceuticals

Qilu Pharmaceutical

Pfizer

Hikma Pharmaceuticals

Fresenius Kabi

Accord Healthcare

Viartis

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Chemotherapy Drugs for Neuroblastoma product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Chemotherapy Drugs for Neuroblastoma, with price, sales, revenue and global market share of Chemotherapy Drugs for Neuroblastoma from 2018 to 2023.

Chapter 3, the Chemotherapy Drugs for Neuroblastoma competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Chemotherapy Drugs for Neuroblastoma breakdown data are shown at

the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022. and Chemotherapy Drugs for Neuroblastoma market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Chemotherapy Drugs for Neuroblastoma.

Chapter 14 and 15, to describe Chemotherapy Drugs for Neuroblastoma sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Chemotherapy Drugs for Neuroblastoma
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Cyclophosphamide
 - 1.3.3 Cisplatin or Carboplatin
 - 1.3.4 Vincristine
 - 1.3.5 Doxorubicin (Adriamycin)
 - 1.3.6 Etoposide
 - 1.3.7 Other
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Hospital
 - 1.4.3 Clinic
 - 1.4.4 Other
- 1.5 Global Chemotherapy Drugs for Neuroblastoma Market Size & Forecast
 - 1.5.1 Global Chemotherapy Drugs for Neuroblastoma Consumption Value (2018 & 2022 & 2029)
 - 1.5.2 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029)
 - 1.5.3 Global Chemotherapy Drugs for Neuroblastoma Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 Baxter Healthcare
 - 2.1.1 Baxter Healthcare Details
 - 2.1.2 Baxter Healthcare Major Business
 - 2.1.3 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
 - 2.1.4 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 Baxter Healthcare Recent Developments/Updates
- 2.2 Ingenus Pharmaceuticals
 - 2.2.1 Ingenus Pharmaceuticals Details

- 2.2.2 Ingenus Pharmaceuticals Major Business
- 2.2.3 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
- 2.2.4 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
- 2.3 ANI Pharmaceuticals
 - 2.3.1 ANI Pharmaceuticals Details
 - 2.3.2 ANI Pharmaceuticals Major Business
 - 2.3.3 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
 - 2.3.4 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.3.5 ANI Pharmaceuticals Recent Developments/Updates
- 2.4 Teva Pharmaceuticals
 - 2.4.1 Teva Pharmaceuticals Details
 - 2.4.2 Teva Pharmaceuticals Major Business
 - 2.4.3 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
 - 2.4.4 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.4.5 Teva Pharmaceuticals Recent Developments/Updates
- 2.5 Qilu Pharmaceutical
 - 2.5.1 Qilu Pharmaceutical Details
 - 2.5.2 Qilu Pharmaceutical Major Business
 - 2.5.3 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services
 - 2.5.4 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.5.5 Qilu Pharmaceutical Recent Developments/Updates
- 2.6 Pfizer
 - 2.6.1 Pfizer Details
 - 2.6.2 Pfizer Major Business
 - 2.6.3 Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services
 - 2.6.4 Pfizer Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 Pfizer Recent Developments/Updates
- 2.7 Hikma Pharmaceuticals
 - 2.7.1 Hikma Pharmaceuticals Details

- 2.7.2 Hikma Pharmaceuticals Major Business
- 2.7.3 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
- 2.7.4 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.7.5 Hikma Pharmaceuticals Recent Developments/Updates
- 2.8 Fresenius Kabi
 - 2.8.1 Fresenius Kabi Details
 - 2.8.2 Fresenius Kabi Major Business
 - 2.8.3 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services
 - 2.8.4 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.8.5 Fresenius Kabi Recent Developments/Updates
- 2.9 Accord Healthcare
 - 2.9.1 Accord Healthcare Details
 - 2.9.2 Accord Healthcare Major Business
 - 2.9.3 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
 - 2.9.4 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Accord Healthcare Recent Developments/Updates
- 2.10 Viatris
 - 2.10.1 Viatris Details
 - 2.10.2 Viatris Major Business
 - 2.10.3 Viatris Chemotherapy Drugs for Neuroblastoma Product and Services
 - 2.10.4 Viatris Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 Viatris Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: CHEMOTHERAPY DRUGS FOR NEUROBLASTOMA BY MANUFACTURER

- 3.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023)
- 3.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023)
- 3.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
- 3.4 Market Share Analysis (2022)

- 3.4.1 Producer Shipments of Chemotherapy Drugs for Neuroblastoma by Manufacturer Revenue (\$MM) and Market Share (%): 2022
- 3.4.2 Top 3 Chemotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
- 3.4.2 Top 6 Chemotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
- 3.5 Chemotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
 - 3.5.1 Chemotherapy Drugs for Neuroblastoma Market: Region Footprint
 - 3.5.2 Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
 - 3.5.3 Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Chemotherapy Drugs for Neuroblastoma Market Size by Region
 - 4.1.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
 - 4.1.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
 - 4.1.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
- 4.2 North America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
- 4.3 Europe Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
- 4.4 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
- 4.5 South America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
- 4.6 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)

5.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2029)

5.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)

6.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2029)

6.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)

7 NORTH AMERICA

7.1 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)

7.2 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)

7.3 North America Chemotherapy Drugs for Neuroblastoma Market Size by Country

7.3.1 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)

7.3.2 North America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)

7.3.3 United States Market Size and Forecast (2018-2029)

7.3.4 Canada Market Size and Forecast (2018-2029)

7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)

8.2 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)

8.3 Europe Chemotherapy Drugs for Neuroblastoma Market Size by Country

8.3.1 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)

8.3.2 Europe Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)

- 8.3.3 Germany Market Size and Forecast (2018-2029)
- 8.3.4 France Market Size and Forecast (2018-2029)
- 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
- 8.3.6 Russia Market Size and Forecast (2018-2029)
- 8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
- 9.2 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
- 9.3 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Market Size by Region
 - 9.3.1 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
 - 9.3.2 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
 - 9.3.3 China Market Size and Forecast (2018-2029)
 - 9.3.4 Japan Market Size and Forecast (2018-2029)
 - 9.3.5 Korea Market Size and Forecast (2018-2029)
 - 9.3.6 India Market Size and Forecast (2018-2029)
 - 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
 - 9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

- 10.1 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
- 10.2 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
- 10.3 South America Chemotherapy Drugs for Neuroblastoma Market Size by Country
 - 10.3.1 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
 - 10.3.2 South America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
 - 10.3.3 Brazil Market Size and Forecast (2018-2029)
 - 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)

11.2 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)

11.3 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Market Size by Country

11.3.1 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)

11.3.2 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)

11.3.3 Turkey Market Size and Forecast (2018-2029)

11.3.4 Egypt Market Size and Forecast (2018-2029)

11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)

11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

12.1 Chemotherapy Drugs for Neuroblastoma Market Drivers

12.2 Chemotherapy Drugs for Neuroblastoma Market Restraints

12.3 Chemotherapy Drugs for Neuroblastoma Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

12.5 Influence of COVID-19 and Russia-Ukraine War

12.5.1 Influence of COVID-19

12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Chemotherapy Drugs for Neuroblastoma and Key Manufacturers

13.2 Manufacturing Costs Percentage of Chemotherapy Drugs for Neuroblastoma

13.3 Chemotherapy Drugs for Neuroblastoma Production Process

13.4 Chemotherapy Drugs for Neuroblastoma Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Chemotherapy Drugs for Neuroblastoma Typical Distributors

14.3 Chemotherapy Drugs for Neuroblastoma Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Table 2. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Table 3. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
- Table 4. Baxter Healthcare Major Business
- Table 5. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
- Table 6. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 7. Baxter Healthcare Recent Developments/Updates
- Table 8. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
- Table 9. Ingenus Pharmaceuticals Major Business
- Table 10. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
- Table 11. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 12. Ingenus Pharmaceuticals Recent Developments/Updates
- Table 13. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
- Table 14. ANI Pharmaceuticals Major Business
- Table 15. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
- Table 16. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 17. ANI Pharmaceuticals Recent Developments/Updates
- Table 18. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
- Table 19. Teva Pharmaceuticals Major Business
- Table 20. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
- Table 21. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales

Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 22. Teva Pharmaceuticals Recent Developments/Updates

Table 23. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 24. Qilu Pharmaceutical Major Business

Table 25. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services

Table 26. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 27. Qilu Pharmaceutical Recent Developments/Updates

Table 28. Pfizer Basic Information, Manufacturing Base and Competitors

Table 29. Pfizer Major Business

Table 30. Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services

Table 31. Pfizer Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 32. Pfizer Recent Developments/Updates

Table 33. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 34. Hikma Pharmaceuticals Major Business

Table 35. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services

Table 36. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 37. Hikma Pharmaceuticals Recent Developments/Updates

Table 38. Fresenius Kabi Basic Information, Manufacturing Base and Competitors

Table 39. Fresenius Kabi Major Business

Table 40. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services

Table 41. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 42. Fresenius Kabi Recent Developments/Updates

Table 43. Accord Healthcare Basic Information, Manufacturing Base and Competitors

Table 44. Accord Healthcare Major Business

Table 45. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services

Table 46. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 47. Accord Healthcare Recent Developments/Updates

Table 48. Viatris Basic Information, Manufacturing Base and Competitors

Table 49. Viatris Major Business

Table 50. Viatris Chemotherapy Drugs for Neuroblastoma Product and Services

Table 51. Viatris Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 52. Viatris Recent Developments/Updates

Table 53. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023) & (K Units)

Table 54. Global Chemotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023) & (USD Million)

Table 55. Global Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 56. Market Position of Manufacturers in Chemotherapy Drugs for Neuroblastoma, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022

Table 57. Head Office and Chemotherapy Drugs for Neuroblastoma Production Site of Key Manufacturer

Table 58. Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint

Table 59. Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint

Table 60. Chemotherapy Drugs for Neuroblastoma New Market Entrants and Barriers to Market Entry

Table 61. Chemotherapy Drugs for Neuroblastoma Mergers, Acquisition, Agreements, and Collaborations

Table 62. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)

Table 63. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)

Table 64. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)

Table 65. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)

Table 66. Global Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2023) & (US\$/Unit)

Table 67. Global Chemotherapy Drugs for Neuroblastoma Average Price by Region (2024-2029) & (US\$/Unit)

Table 68. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)

Table 69. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)

Table 70. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2023) & (USD Million)

Table 71. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type (2024-2029) & (USD Million)

Table 72. Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2023) & (US\$/Unit)

Table 73. Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2024-2029) & (US\$/Unit)

Table 74. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)

Table 75. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)

Table 76. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2023) & (USD Million)

Table 77. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application (2024-2029) & (USD Million)

Table 78. Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2023) & (US\$/Unit)

Table 79. Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2024-2029) & (US\$/Unit)

Table 80. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)

Table 81. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)

Table 82. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)

Table 83. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)

Table 84. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)

Table 85. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)

Table 86. North America Chemotherapy Drugs for Neuroblastoma Consumption Value

by Country (2018-2023) & (USD Million)

Table 87. North America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)

Table 88. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)

Table 89. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)

Table 90. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)

Table 91. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)

Table 92. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)

Table 93. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)

Table 94. Europe Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)

Table 95. Europe Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)

Table 96. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)

Table 97. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)

Table 98. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)

Table 99. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)

Table 100. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)

Table 101. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)

Table 102. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)

Table 103. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)

Table 104. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)

Table 105. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)

Table 106. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)

Table 107. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)

Table 108. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)

Table 109. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)

Table 110. South America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)

Table 111. South America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)

Table 112. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)

Table 113. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)

Table 114. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)

Table 115. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)

Table 116. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)

Table 117. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)

Table 118. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)

Table 119. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)

Table 120. Chemotherapy Drugs for Neuroblastoma Raw Material

Table 121. Key Manufacturers of Chemotherapy Drugs for Neuroblastoma Raw Materials

Table 122. Chemotherapy Drugs for Neuroblastoma Typical Distributors

Table 123. Chemotherapy Drugs for Neuroblastoma Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Chemotherapy Drugs for Neuroblastoma Picture

Figure 2. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Type in 2022

Figure 4. Cyclophosphamide Examples

Figure 5. Cisplatin or Carboplatin Examples

Figure 6. Vincristine Examples

Figure 7. Doxorubicin (Adriamycin) Examples

Figure 8. Etoposide Examples

Figure 9. Other Examples

Figure 10. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 11. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Application in 2022

Figure 12. Hospital Examples

Figure 13. Clinic Examples

Figure 14. Other Examples

Figure 15. Global Chemotherapy Drugs for Neuroblastoma Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 16. Global Chemotherapy Drugs for Neuroblastoma Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 17. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029) & (K Units)

Figure 18. Global Chemotherapy Drugs for Neuroblastoma Average Price (2018-2029) & (US\$/Unit)

Figure 19. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Manufacturer in 2022

Figure 20. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Manufacturer in 2022

Figure 21. Producer Shipments of Chemotherapy Drugs for Neuroblastoma by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021

Figure 22. Top 3 Chemotherapy Drugs for Neuroblastoma Manufacturer (Consumption Value) Market Share in 2022

Figure 23. Top 6 Chemotherapy Drugs for Neuroblastoma Manufacturer (Consumption

Value) Market Share in 2022

Figure 24. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)

Figure 25. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)

Figure 26. North America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)

Figure 27. Europe Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)

Figure 28. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)

Figure 29. South America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)

Figure 30. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)

Figure 31. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)

Figure 32. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Type (2018-2029)

Figure 33. Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029) & (US\$/Unit)

Figure 34. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)

Figure 35. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Application (2018-2029)

Figure 36. Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029) & (US\$/Unit)

Figure 37. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)

Figure 38. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)

Figure 39. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)

Figure 40. North America Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)

Figure 41. United States Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 42. Canada Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 43. Mexico Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 44. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)

Figure 45. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)

Figure 46. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)

Figure 47. Europe Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)

Figure 48. Germany Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. France Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 50. United Kingdom Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 51. Russia Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 52. Italy Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 53. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)

Figure 54. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)

Figure 55. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)

Figure 56. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)

Figure 57. China Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. Japan Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. Korea Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 60. India Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 61. Southeast Asia Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 62. Australia Chemotherapy Drugs for Neuroblastoma Consumption Value and

Growth Rate (2018-2029) & (USD Million)

Figure 63. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)

Figure 64. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)

Figure 65. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)

Figure 66. South America Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)

Figure 67. Brazil Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 68. Argentina Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 69. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)

Figure 70. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)

Figure 71. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)

Figure 72. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)

Figure 73. Turkey Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 74. Egypt Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 75. Saudi Arabia Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 76. South Africa Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 77. Chemotherapy Drugs for Neuroblastoma Market Drivers

Figure 78. Chemotherapy Drugs for Neuroblastoma Market Restraints

Figure 79. Chemotherapy Drugs for Neuroblastoma Market Trends

Figure 80. Porters Five Forces Analysis

Figure 81. Manufacturing Cost Structure Analysis of Chemotherapy Drugs for Neuroblastoma in 2022

Figure 82. Manufacturing Process Analysis of Chemotherapy Drugs for Neuroblastoma

Figure 83. Chemotherapy Drugs for Neuroblastoma Industrial Chain

Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 85. Direct Channel Pros & Cons

Figure 86. Indirect Channel Pros & Cons

Figure 87. Methodology

Figure 88. Research Process and Data Source

I would like to order

Product name: Global Chemotherapy Drugs for Neuroblastoma Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G53CDFC7CEDBEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G53CDFC7CEDBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

